Form 8-K - Current report:
SEC Accession No. 0001104659-25-016712
Filing Date
2025-02-25
Accepted
2025-02-25 07:12:12
Documents
15
Period of Report
2025-02-20
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm257490d1_8k.htm   iXBRL 8-K 27272
2 EXHIBIT 99.1 tm257490d1_ex99-1.htm EX-99.1 13987
6 GRAPHIC tm257490d1_ex99-1img001.jpg GRAPHIC 3853
  Complete submission text file 0001104659-25-016712.txt   227510

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lvtx-20250220.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lvtx-20250220_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lvtx-20250220_pre.xml EX-101.PRE 22375
18 EXTRACTED XBRL INSTANCE DOCUMENT tm257490d1_8k_htm.xml XML 3668
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40241 | Film No.: 25659383
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)